AAN.com
Quick search in Citations
AnywhereCitation
Advanced Search
Trending Terms:
Clinical/Scientific Notes
February 8, 2017

11C-PBR28 PET detects translocator protein in a patient with astrocytoma and Alzheimer disease

William C. Kreisl, MD, Robin Lawrence, Emily Page, Andrew F. Teich, MD, PhD, Deepa S. Subramaniam, MD, MSc, Robert B. Innis, MD, PhD, and R. Scott Turner, MD, PhDAuthors Info & Affiliations
March 7, 2017 issue
88 (10) 1001-1004
https://doi.org/10.1212/WNL.0000000000003693
Letters to the Editor
Track CitationsAdd to favorites
Get Access

Abstract

A 66-year-old woman with probable Alzheimer disease (AD) enrolled in National Institute of Mental Health protocols 09-M-0198 and 08-M-0066. The protocols were approved by the Combined Neurosciences Institutional Review Board, and the patient gave informed consent before entering the study. Brian MRI showed diffuse atrophy and a small T2 hyperintensity in the right posterior temporal region (0.4 × 1.4 cm) interpreted as nonspecific gliosis (figure). 18Fluorodeoxyglucose PET revealed bilateral temporo-parietal hypometabolism (with no hypermetabolism in the area of the T2 hyperintensity) and 11C-Pittsburgh compound B PET imaging showed fibrillar β-amyloid retention, both consistent with AD pathophysiology. PET imaging with 11C-PBR28, a radioligand for the 18 kDa translocator protein (TSPO), was performed to measure microglial activation. Diffuse 11C-PBR28 binding was found in gray matter, with a small focus of increased binding colocalized to the T2 hyperintensity. 11C-PR28 binding was 19% greater in the T2 hyperintensity than in an identical volume in contralateral brain (figure).

Get full access to this article

View all available purchase options and get full access to this article.

Get Access

References

1.
Su Z, Roncaroli F, Durrenberger PF, et al. The 18-kDa mitochondrial translocator protein in human gliomas: an 11C-(R)PK11195 PET imaging and neuropathology study. J Nucl Med 2015;56:512–517.
Crossref
PubMed
Google Scholar
2.
Cosenza-Nashat M, Zhao ML, Suh HS, et al. Expression of the translocator protein of 18 kDa by microglia, macrophages and astrocytes based on immunohistochemical localization in abnormal human brain. Neuropathol Appl Neurobiol 2009;35:306–328.
Crossref
PubMed
Google Scholar
3.
Owen DR, Matthews PM. Imaging brain microglial activation using positron emission tomography and translocator protein-specific radioligands. Int Rev Neurobiol 2011;101:19–39.
Crossref
PubMed
Google Scholar
4.
Miettinen H, Kononen J, Haapasalo H, et al. Expression of peripheral-type benzodiazepine receptor and diazepam binding inhibitor in human astrocytomas: relationship to cell proliferation. Cancer Res 1995;55:2691–2695.
PubMed
Google Scholar
5.
Kreisl WC, Lyoo CH, McGwier M, et al. In vivo radioligand binding to translocator protein correlates with severity of Alzheimer's disease. Brain 2013;136:2228–2238.
Crossref
PubMed
Google Scholar
6.
Kreisl WC, Lyoo CH, Liow JS, et al. 11C-PBR28 binding to translocator protein increases with progression of Alzheimer's disease. Neurobiol Aging 2016;44:53–61.
Crossref
PubMed
Google Scholar

Information & Authors

Information

Published In

Neurology®
Volume 88 • Number 10 • March 7, 2017
Pages: 1001-1004
PubMed: 28179461

Copyright

© 2017 American Academy of Neurology.

Publication History

Received: August 17, 2016
Accepted: December 6, 2016
Published online: February 8, 2017
Published in issue: March 7, 2017

Permissions

Request permissions for this article.

Funding Information

Study funding: Funded by the National Institute of Mental Health project numbers ZIAMH002852 and ZIAMH0022793 under clinicaltrials.gov identifiers NCT00955422 and NCT00613119 (protocols 08-M-0066 and 09-M-0198).Disclosure: The authors report no disclosures relevant to the manuscript. Go to Neurology.org for full disclosures.

Authors

Affiliations & Disclosures

William C. Kreisl, MD
From the Molecular Imaging Branch (W.C.K., E.P., R.B.I.), National Institute of Mental Health, Bethesda, MD; Taub Institute (W.C.K.), Columbia University Medical Center (A.F.T.), New York, NY; and Memory Disorders Program (R.L., R.S.T.) and Lombardi Comprehensive Cancer Center (D.S.S.), Georgetown University, Washington, DC.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
American College of Neuropsychopharmacology - funding for travel - reimbursement of $320.50 of travel costs .
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
1. Merck 2. AstraZeneca
Research Support, Government Entities:
1.
1. NIH, KAG052633A, Role: PI, 04/01/16 ? 03/31/21 2. NIH, P50AG008702 Role: Co-investigator of the Clinical Core; Pilot Leader, 10/01/14 - 05/31/20
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Robin Lawrence
From the Molecular Imaging Branch (W.C.K., E.P., R.B.I.), National Institute of Mental Health, Bethesda, MD; Taub Institute (W.C.K.), Columbia University Medical Center (A.F.T.), New York, NY; and Memory Disorders Program (R.L., R.S.T.) and Lombardi Comprehensive Cancer Center (D.S.S.), Georgetown University, Washington, DC.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
Georgetown University has received clinical research support from Lilly, Merck, Biogen, and Toyama.
Research Support, Government Entities:
1.
Georgetown University has received clinical research support from NIH.
Research Support, Academic Entities:
1.
Georgetown University
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Emily Page
From the Molecular Imaging Branch (W.C.K., E.P., R.B.I.), National Institute of Mental Health, Bethesda, MD; Taub Institute (W.C.K.), Columbia University Medical Center (A.F.T.), New York, NY; and Memory Disorders Program (R.L., R.S.T.) and Lombardi Comprehensive Cancer Center (D.S.S.), Georgetown University, Washington, DC.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Andrew F. Teich, MD, PhD
From the Molecular Imaging Branch (W.C.K., E.P., R.B.I.), National Institute of Mental Health, Bethesda, MD; Taub Institute (W.C.K.), Columbia University Medical Center (A.F.T.), New York, NY; and Memory Disorders Program (R.L., R.S.T.) and Lombardi Comprehensive Cancer Center (D.S.S.), Georgetown University, Washington, DC.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
Expert Connect, $3,000 in March 2015 for consulting on aducanumab phase II trial from Biogen.
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NIH-NIA
Research Support, Academic Entities:
1.
Columbia University
Research Support, Foundations and Societies:
1.
Alzheimer's Association
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Deepa S. Subramaniam, MD, MSc
From the Molecular Imaging Branch (W.C.K., E.P., R.B.I.), National Institute of Mental Health, Bethesda, MD; Taub Institute (W.C.K.), Columbia University Medical Center (A.F.T.), New York, NY; and Memory Disorders Program (R.L., R.S.T.) and Lombardi Comprehensive Cancer Center (D.S.S.), Georgetown University, Washington, DC.
Disclosure
Scientific Advisory Boards:
1.
Astra Zeneca, served on advisory board in June 2015
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
Georgetown University received research support for industry sponsored studies that I was/am PI for (entities include: 1. Genentech 2. Lilly 3. Bristol Myers Squibb 4. Pfizer); the only studies in brain tumors was BMS.
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Robert B. Innis, MD, PhD
From the Molecular Imaging Branch (W.C.K., E.P., R.B.I.), National Institute of Mental Health, Bethesda, MD; Taub Institute (W.C.K.), Columbia University Medical Center (A.F.T.), New York, NY; and Memory Disorders Program (R.L., R.S.T.) and Lombardi Comprehensive Cancer Center (D.S.S.), Georgetown University, Washington, DC.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
Janssen research grant
Research Support, Government Entities:
1.
NIMH Intramural Research Program
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
R. Scott Turner, MD, PhD
From the Molecular Imaging Branch (W.C.K., E.P., R.B.I.), National Institute of Mental Health, Bethesda, MD; Taub Institute (W.C.K.), Columbia University Medical Center (A.F.T.), New York, NY; and Memory Disorders Program (R.L., R.S.T.) and Lombardi Comprehensive Cancer Center (D.S.S.), Georgetown University, Washington, DC.
Disclosure
Scientific Advisory Boards:
1.
NIA, Data Safety and Monitoring Board, 2014-present.
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
Frontiers in Neuroscience, Editorial Board, 2008-present. Aging, Neuropsychology and Cognition, Editorial Board, 2006-present.
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
Support for clinical research to Georgetown University from Biogen, Lilly, Merck, Toyama, and Novartis, 2015-present.
Research Support, Government Entities:
1.
NIA U01 AG10483, Project PI and Member of Steering Committee, 2006- present.
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author

Notes

Correspondence to Dr. Kreisl: [email protected]

Metrics & Citations

Metrics

Citation information is sourced from Crossref Cited-by service.

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
    • Stefanie Quach,
    • Adrien Holzgreve,
    • Lena Kaiser,
    • Marcus Unterrainer,
    • Franziska J. Dekorsy,
    • Debie V. Nelwan,
    • Laura M. Bartos,
    • Sabrina V. Kirchleitner,
    • Jonathan Weller,
    • Lorraine Weidner,
    • Maximilian Niyazi,
    • Viktoria C. Ruf,
    • Jochen Herms,
    • Sophia Stöcklein,
    • Christian Wetzel,
    • Markus J. Riemenschneider,
    • Louisa v. Baumgarten,
    • Niklas Thon,
    • Matthias Brendel,
    • Rainer Rupprecht,
    • Peter Bartenstein,
    • Joerg-Christian Tonn,
    • Nathalie L. Albert,
    TSPO PET signal using [18F]GE180 is associated with survival in recurrent gliomas, European Journal of Nuclear Medicine and Molecular Imaging, 50, 3, (859-869), (2022).https://doi.org/10.1007/s00259-022-06006-1
    Crossref
    • Laura M. Bartos,
    • Sabrina V. Kirchleitner,
    • Jens Blobner,
    • Karin Wind,
    • Lea H. Kunze,
    • Adrien Holzgreve,
    • Lukas Gold,
    • Artem Zatcepin,
    • Zeynep Ilgin Kolabas,
    • Selin Ulukaya,
    • Lorraine Weidner,
    • Stefanie Quach,
    • Denise Messerer,
    • Peter Bartenstein,
    • Joerg C. Tonn,
    • Markus J. Riemenschneider,
    • Sibylle Ziegler,
    • Louisa von Baumgarten,
    • Nathalie L. Albert,
    • Matthias Brendel,
    18 kDa translocator protein positron emission tomography facilitates early and robust tumor detection in the immunocompetent SB28 glioblastoma mouse model, Frontiers in Medicine, 9, (2022).https://doi.org/10.3389/fmed.2022.992993
    Crossref
    • Fabien Chauveau,
    • Guillaume Becker,
    • Hervé Boutin,
    Have (R)-[11C]PK11195 challengers fulfilled the promise? A scoping review of clinical TSPO PET studies, European Journal of Nuclear Medicine and Molecular Imaging, 49, 1, (201-220), (2021).https://doi.org/10.1007/s00259-021-05425-w
    Crossref
    • Bastian Zinnhardt,
    • Federico Roncaroli,
    • Claudia Foray,
    • Erjon Agushi,
    • Bahiya Osrah,
    • Gaëlle Hugon,
    • Andreas H. Jacobs,
    • Alexandra Winkeler,
    Imaging of the glioma microenvironment by TSPO PET, European Journal of Nuclear Medicine and Molecular Imaging, 49, 1, (174-185), (2021).https://doi.org/10.1007/s00259-021-05276-5
    Crossref
    • Shamia Faison,
    • Roberto Gomeni,
    • Shannon Mendes,
    • Welton O'Neal,
    • Stefan Schwabe,
    • Azmi Nasser,

    Predicted Efficacy of Once-Daily Extended-Release Oxcarbazepine (Oxtellar XR®) Monotherapy in Adults and Children with Partial-Onset Seizures: Exposure-Response Modeling and Simulation

    ,     Clinical Pharmacology: Advances and Applications, Volume 12, (135-147), (2020).https://doi.org/10.2147/CPAA.S256972
    Crossref
    • James Zou,
    • Sha Tao,
    • Aubrey Johnson,
    • Zeljko Tomljanovic,
    • Krista Polly,
    • Julia Klein,
    • Qolamreza R. Razlighi,
    • Adam M. Brickman,
    • Seonjoo Lee,
    • Yaakov Stern,
    • William Charles Kreisl,
    Microglial activation, but not tau pathology, is independently associated with amyloid positivity and memory impairment, Neurobiology of Aging, 85, (11-21), (2020).https://doi.org/10.1016/j.neurobiolaging.2019.09.019
    Crossref
    • F. Riganello,
    • G. Napoletano,
    • M. D. Cortese,
    • F. Arcuri,
    • A. Solano,
    • L. F. Lucca,
    • P. Tonin,
    • A. Soddu,
    What impact can hospitalization environment produce on the ANS functioning in patients with Unresponsive Wakefulness Syndrome? – 24-hour monitoring, Brain Injury, 33, 10, (1347-1353), (2019).https://doi.org/10.1080/02699052.2019.1641841
    Crossref
    • Jinbin Xu,
    • Jianjun Sun,
    • Richard J. Perrin,
    • Robert H. Mach,
    • Kelly R. Bales,
    • John C. Morris,
    • Tammie L. S. Benzinger,
    • David M. Holtzman,
    Translocator protein in late stage Alzheimer’s disease and Dementia with Lewy bodies brains, Annals of Clinical and Translational Neurology, 6, 8, (1423-1434), (2019).https://doi.org/10.1002/acn3.50837
    Crossref
    • Adam Odolil,
    • Amy E. Wright,
    • Lynsey M. Keator,
    • Shannon M. Sheppard,
    • Bonnie Breining,
    • Donna C. Tippett,
    • Argye E. Hillis,
    Leukoaraiosis severity predicts rate of decline in primary progressive aphasia, Aphasiology, 34, 3, (365-375), (2019).https://doi.org/10.1080/02687038.2019.1594152
    Crossref
    • Bradley J. Adame,
    • Steven R. Corman,
    Vested Interests and Perceived Risk of Concussion Consequences among Power-5 College Athletes, Health Communication, 34, 13, (1673-1682), (2018).https://doi.org/10.1080/10410236.2018.1517707
    Crossref

View Options

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.

If you need immediate support or to place an order, please call or email customer service:

  • 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
  • 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
  • [email protected]

We appreciate your patience during this time and apologize for any inconvenience.

View options

PDF and All Supplements

Download PDF and Supplementary Material

Full Text

View Full Text

Full Text HTML

View Full Text HTML

Figures

Tables

Media

Share

Share

Share article link

Share

View full text|Download PDF